References
- Langford C. A., Talar‐Williams C., Sneller M. C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 15:51: 278–83
- D'Cruz D. P. Mycophenolate mofetil in systemic vasculitis. Lupus 2005; 14: S55–7
- Ginzler E. M., Dooley M. A., Aranow C., Kim M. Y., Buyon J., Merrill J. T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 24; 353: 2219–28
- Uthman I. Pharmacological therapy of vasculitis: an update. Curr Opin Pharmacol 2004; 4: 177–182
- Thomas‐Golbanov C., Sridharan S. Novel therapies in vasculitis. Expert Opin Investig Drugs 2001; 10: 1279–89
- Langford C. A. Management of systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15: 281–97
- Lee W. M. Drug induced hepatotoxity. N Engl J Med 2003; 349: 474–85
- Balal M., Demir E., Paydas S., Sertdemir Y., Erken U. Uncommon side effect of MMF in renal transplant recipients. Ren Fail 2005; 27: 591–4